Table 1.
Baseline characteristics of Risk & Prevention participants
| % or mean (SD) | |
| Age (years) | |
| Mean | 63.9 (9.5) |
| ≤50 | 7.4 |
| 51-59 | 22.9 |
| 60-69 | 39.6 |
| 70-79 | 27.0 |
| ≥80 | 3.0 |
| Males | 61.5 |
| Previous CVD | 29.6 |
| Cardiovascular risk factors | |
| Hypertension | 84.6 |
| Hypercholesterolemia | 71.1 |
| Diabetes mellitus | 59.9 |
| Obesity | 48.6 |
| Family history of premature CVD | 31.1 |
| Cigarette smokers | 21.7 |
| Unhealthy diet | 63.9 |
| Physical inactivity | 56.1 |
| BMI (kg/m2) | 29.3 (4.9) |
| SBP (mmHg) | 140.2 (15.2) |
| DBP (mmHg) | 82.7 (8.2) |
| Heart rate (bpm) | 74.4 (8.4) |
| Total cholesterol (mg/dL) | 215.9 (42.6) |
| LDL cholesterol (mg/dL) | 132.1 (36.4) |
| HDL cholesterol (mg/dL) | 51.1 (13.3) |
| Triglycerides (mg/dL) | 168.7 (99.8) |
| Fasting blood glucose (mg/dL) | 132.8 (46.7) |
| * HbA1C (%) | 7.0 (1.5) |
| Medical treatment | |
| ACE inhibitors | 45.1 |
| ARBs | 21.9 |
| Diuretics | 41.5 |
| Calcium - channel blockers | 28.2 |
| β-blockers | 20.6 |
| Oral hypoglycemic drugs | 44.1 |
| Insulin | 6.6 |
| Statins | 41.1 |
| Antiplatelet agents | 41.4 |
*in diabetic patients
CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein, HDL, high-density lipoprotein, HbA1C, glycated hemoglobin, ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker